Literature DB >> 9518514

In situ characterization of oxalate transport across the basolateral membrane of the proximal tubule.

E Brändle1, U Bernt, R E Hautmann.   

Abstract

Oxalate transport across the contraluminal membrane of the proximal tubule was studied in vivo using the "capillary stopped flow microperfusion method" (Pflügers Arch 400:250-256, 1984). Cellular uptake of oxalate was characteristic of a carrier-mediated transport process (Jmax = 1.6 +/- 0.6 pmol/s per cm proximal tubular length, Km = 2.03 +/- 0.77 mmol/l). Sulphate inhibited oxalate transport in a dose-dependent manner (Ki-value = 1.53 +/- 0.38 mmol/l). Sulphate transport across the basolateral membrane was also characteristic of a carrier- mediated transport process (Jmax = 1.83 +/- 0.56 pmol/s per cm proximal tubular length, Km = 1.37 +/- 0.57 mmol/l). Oxalate inhibited the sulphate transport in a dose-dependent manner (Ki = 2. 06 +/- 0.82 mmol/l). No significant differences were found between the Ki values and the Km values of the two substances, indicating that oxalate and sulphate are transported by the same carrier across the basolateral membrane of the proximal tubule. Oxalate transport was not dependent on the extracellular sodium or potassium concentration. Bicarbonate competitively inhibited the oxalate transport. Chloride significantly inhibited the oxalate transport, but not dose dependently. It is, therefore, suggested that oxalate is transported into the cell of the proximal tubule in exchange for sulphate or bicarbonate. The dose-independent inhibition by chloride is suggested to be mediated by the coupling of the sulphate (bicarbonate)/oxalate exchanger with the chloride/bicarbonate exchanger at the basolateral membrane of the proximal tubule. This, furthermore, suggests that the transport of oxalate or sulphate across the basolateral membrane might be indirectly coupled with the reabsorption of chloride at this membrane side.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9518514     DOI: 10.1007/s004240050592

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  5 in total

1.  Why oral calcium supplements may reduce renal stone disease: report of a clinical pilot study.

Authors:  C P Williams; D F Child; P R Hudson; G K Davies; M G Davies; R John; P S Anandaram; A R De Bolla
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

2.  Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria.

Authors:  Nancy S Krieger; John R Asplin; Kevin K Frick; Ignacio Granja; Christopher D Culbertson; Adeline Ng; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

3.  The influence of oxalate on renal epithelial and interstitial cells.

Authors:  Thomas Knoll; Annette Steidler; Lutz Trojan; Sreedhar Sagi; Axel Schaaf; Benito Yard; Maurice Stephan Michel; Peter Alken
Journal:  Urol Res       Date:  2004-06-10

4.  Hyperoxaluric rats do not exhibit alterations in renal expression patterns of Slc26a1 (SAT1) mRNA or protein.

Authors:  Robert W Freel; Marguerite Hatch
Journal:  Urol Res       Date:  2012-05-10

5.  The liver and kidney expression of sulfate anion transporter sat-1 in rats exhibits male-dominant gender differences.

Authors:  Hrvoje Brzica; Davorka Breljak; Wolfgang Krick; Mila Lovrić; Gerhard Burckhardt; Birgitta C Burckhardt; Ivan Sabolić
Journal:  Pflugers Arch       Date:  2008-11-11       Impact factor: 3.657

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.